Evidence map›Paper›PMID 30623280›Full record

ReviewMolecular biology reports2019

Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles.

Fariba Rad, Mohammad Ghorbani, Amaneh Mohammadi Roushandeh, Mehryar Habibi Roudkenar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Mesenchymal stromal cells protect tissues from Th1 immune responses via IL-11 secretion.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Organism-Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Fariba RadCellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Mohammad GhorbaniDepartment of Hematology and Blood Banking, Gonabad University of Medical Sciences, Gonabad, Iran.
Amaneh Mohammadi RoushandehMedical Biotechnology Research Center, Paramedicine Faculty, Guilan University of Medical Sciences, Rasht, Iran.
Mehryar Habibi RoudkenarCardiovascular Disease Research Center, Department of Cardiology, School of Medicine, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran. roudkenar@gums.ac.ir.
Guilan University of Medical Sciences · IRGonabad University of Medical Sciences · IRYasuj University of Medical Sciences · IR

Funding

Guilan University of Medical Sciences IR.GUMS.REC.1396.343
6 · The paper itself

Abstract

In autoimmune disease body's own immune system knows healthy cells as undesired and foreign cells. Over 80 types of autoimmune diseases have been recognized. Currently, at clinical practice, treatment strategies for autoimmune disorders are based on relieving symptoms and preventing difficulties. In other words, there is no effective and useful therapy up to now. It has been well-known that mesenchymal stem cells (MSCs) possess immunomodulatory effects. This strongly suggests that MSCs might be as a novel modality for treatment of autoimmune diseases. Supporting this notion a few preclinical and clinical studies indicate that MSCs ameliorate autoimmune disorders. Interestingly, it has been found that the beneficial effects of MSCs in autoimmune disorders are not relying only on direct cell-to-cell communication but on their capability to produce a broad range of paracrine factors including growth factors, cytokines and extracellular vehicles (EVs). EVs are multi-signal messengers that play a serious role in intercellular signaling through carrying cargo such as mRNA, miRNA, and proteins. Numerous studies have shown that MSC-derived EVs are able to mimic the effects of the cell of origin on immune cells. In this review, we discuss the current studies dealing with MSC-based therapies in autoimmune diseases and provide a vision and highlight in order to introduce MSC-derived EVs as an alternative and emerging modality for autoimmune disorders.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsAutoimmune DiseasesClinical Trials as TopicExtracellular VesiclesHumansImmunosuppression TherapyMesenchymal Stem CellsAutoimmune diseasesCell-free therapyExtracellular vesiclesImmune cellsMesenchymal stem cells

Identifiers

PMID30623280
OpenAlexW2909511612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.